|Model|SBML|SEDML|broken-ref|valid-sbml|valid-sbml-units|valid-sedml|tellurium|
|---|---|---|---|---|---|---|---|
|[BIOMD0000000005](https://www.ebi.ac.uk/biomodels/BIOMD0000000005)<br/><sup>Tyson1991 - Cell Cycle 6 var</sup>|BIOMD0000000005_url.xml|BIOMD0000000005_SED-ML.xml|False| | | |
|[BIOMD0000000297](https://www.ebi.ac.uk/biomodels/BIOMD0000000297)<br/><sup>Ciliberto2003_Morphogenesis_Checkpoint</sup>|BIOMD0000000297_url.xml|f3.sedml|True| | | |
|[BIOMD0000000459](https://www.ebi.ac.uk/biomodels/BIOMD0000000459)<br/><sup>Liebal2012 - B.subtilis post-transcriptional instability model</sup>|BIOMD0000000459_url.xml|BIOMD0000000459-SEDML.xml|False| | | |
|[BIOMD0000000460](https://www.ebi.ac.uk/biomodels/BIOMD0000000460)<br/><sup>Liebal2012 - B.subtilis sigB proteolysis model</sup>|BIOMD0000000460_url.xml|BIOMD0000000460-SEDML.xml|False| | | |
|[BIOMD0000000461](https://www.ebi.ac.uk/biomodels/BIOMD0000000461)<br/><sup>Liebal2012 - B.subtilis transcription inhibition model</sup>|BIOMD0000000461_url.xml|BIOMD0000000461-SEDML.xml|False| | | |
|[BIOMD0000000539](https://www.ebi.ac.uk/biomodels/BIOMD0000000539)<br/><sup>François2005 - Mixed Feedback Loop (two-gene network)</sup>|BIOMD0000000539_url.xml|BIOMD0000000539.sedml|False| | | |
|[BIOMD0000000546](https://www.ebi.ac.uk/biomodels/BIOMD0000000546)<br/><sup>Miao2010 - Innate and adaptive immune responses to primary Influenza A Virus infection_1_1</sup>|BIOMD0000000546.xml|BIOMD0000000546.sedml|False| | | |
|[BIOMD0000000596](https://www.ebi.ac.uk/biomodels/BIOMD0000000596)<br/><sup>Philipson2015 - Innate immune response modulated by NLRX1</sup>|Philipson2015.xml|Philipson2015.sedml|True| | | |
|[BIOMD0000000618](https://www.ebi.ac.uk/biomodels/BIOMD0000000618)<br/><sup>Krohn2011 - Cerebral amyloid-β proteostasis regulated by membrane transport protein ABCC1</sup>|BIOMD0000000618_url.xml|BIOMD0000000618_SED-ML.xml|False| | | |
|[BIOMD0000000623](https://www.ebi.ac.uk/biomodels/BIOMD0000000623)<br/><sup>Orton2009 - Modelling cancerous mutations in the EGFR/ERK pathway - EGF Model</sup>|BIOMD0000000623_url.xml|Orton2009.sedml|True| | | |
|[BIOMD0000000627](https://www.ebi.ac.uk/biomodels/BIOMD0000000627)<br/><sup>Winter2017 - Brain Energy Metabolism with PPP</sup>|BIOMD0000000627_url.xml|BIOMD0000000627_SED-ML.xml|False| | | |
|[BIOMD0000000643](https://www.ebi.ac.uk/biomodels/BIOMD0000000643)<br/><sup>Musante2017 - Switching behaviour of PP2A inhibition by ARPP-16 - mutual inhibitions</sup>|BIOMD0000000643_url.xml|ARPP-16_Layer1_mutualInhibitions.sedml|False| | | |
|[BIOMD0000000644](https://www.ebi.ac.uk/biomodels/BIOMD0000000644)<br/><sup>Musante2017 - Switching behaviour of PP2A inhibition by ARPP-16 - mutual inhibitions and PKA inhibits MAST3</sup>|BIOMD0000000644_url.xml|ARPP-16_Layer1and2_mutualInhibitions_PKAinhibitsMAST3.sedml|False| | | |
|[BIOMD0000000645](https://www.ebi.ac.uk/biomodels/BIOMD0000000645)<br/><sup>Musante2017 - Switching behaviour of PP2A inhibition by ARPP-16 - mutual inhibitions and PKA inhibits MAST3 and dominant negative effect</sup>|BIOMD0000000645_url.xml|ARPP-16_Layer1and2and3_mutualInhibitions_PKAinhibitsMAST3_dominantNegative.sedml|False| | | |
|[BIOMD0000000646](https://www.ebi.ac.uk/biomodels/BIOMD0000000646)<br/><sup>Barr2016 - All-or-nothing G1/S transition</sup>|BIOMD0000000646_url.xml|Barr2016.sedml|False| | | |
|[BIOMD0000000647](https://www.ebi.ac.uk/biomodels/BIOMD0000000647)<br/><sup>Kwang2003 - The influence of RKIP on the ERK signaling pathway</sup>|BIOMD0000000647_url.xml|BIOMD0000000647.sedml|False| | | |
|[BIOMD0000000650](https://www.ebi.ac.uk/biomodels/BIOMD0000000650)<br/><sup>Owen1998 - Tumour  treatment model</sup>|BIOMD0000000650_url.xml|MODEL1708250002_treatment_start10.sedml|True| | | |
|[BIOMD0000000651](https://www.ebi.ac.uk/biomodels/BIOMD0000000651)<br/><sup>Nguyen2016 - Feedback regulation in cell signalling: Lessons for cancer therapeutics</sup>|BIOMD0000000651_url.xml|BIOMD0000000651.sedml|False| | | |
|[BIOMD0000000658](https://www.ebi.ac.uk/biomodels/BIOMD0000000658)<br/><sup>Lee2003 - Roles of APC and Axin in Wnt Pathway (without regulatory loop)</sup>|BIOMD0000000658_url.xml|MODEL1708310000_edited.sedml|True| | | |
|[BIOMD0000000661](https://www.ebi.ac.uk/biomodels/BIOMD0000000661)<br/><sup>Webb2002 - Fas/FasL mediated tumor T-cell interaction</sup>|BIOMD0000000661_url.xml|MODEL1006230046.sedml|False| | | |
|[BIOMD0000000662](https://www.ebi.ac.uk/biomodels/BIOMD0000000662)<br/><sup>Moore2004 - Chronic Myeloid Leukemic cells and T-lymphocyte interaction</sup>|BIOMD0000000662_url.xml|Moore2004.sedml|True| | | |
|[BIOMD0000000663](https://www.ebi.ac.uk/biomodels/BIOMD0000000663)<br/><sup>Wodarz2007 - HIV/CD4 T-cell interaction</sup>|BIOMD0000000663_url.xml|Wodarz2007_model_2.sedml|True| | | |
|[BIOMD0000000664](https://www.ebi.ac.uk/biomodels/BIOMD0000000664)<br/><sup>Muller2008 - Simplified MAPK activation Dynamics (Model B)</sup>|BIOMD0000000664_url.xml|MODEL8687732743.sedml|True| | | |
|[BIOMD0000000665](https://www.ebi.ac.uk/biomodels/BIOMD0000000665)<br/><sup>Fallon2000 - Interleukin-2 dynamics</sup>|BIOMD0000000665_url.xml|MODEL1006230001.sedml|True| | | |
|[BIOMD0000000666](https://www.ebi.ac.uk/biomodels/BIOMD0000000666)<br/><sup>Pappalardo2016 - PI3K/AKT and MAPK Signaling Pathways in Melanoma Cancer</sup>|BIOMD0000000666_url.xml|BIOMD0000000666.sedml|True| | | |
|[BIOMD0000000667](https://www.ebi.ac.uk/biomodels/BIOMD0000000667)<br/><sup>Hornberg2005 - MAPKsignalling</sup>|BIOMD0000000667_url.xml|MODEL0848279215.sedml|True| | | |
|[BIOMD0000000668](https://www.ebi.ac.uk/biomodels/BIOMD0000000668)<br/><sup>Zhu2015 - Combined gemcitabine and birinapant in pancreatic cancer cells - basic PD model</sup>|BIOMD0000000668_url.xml|MODEL1604270000_basic.sedml|True| | | |
|[BIOMD0000000669](https://www.ebi.ac.uk/biomodels/BIOMD0000000669)<br/><sup>Zhu2015 - Combined gemcitabine and birinapant in pancreatic cancer cells - mechanistic PD model</sup>|BIOMD0000000669_url.xml|MODEL1604270001_mechanistic.sedml|True| | | |
|[BIOMD0000000670](https://www.ebi.ac.uk/biomodels/BIOMD0000000670)<br/><sup>Owen1998 - tumour growth model</sup>|BIOMD0000000670_url.xml|MODEL1708240000.sedml|True| | | |
|[BIOMD0000000671](https://www.ebi.ac.uk/biomodels/BIOMD0000000671)<br/><sup>Murphy2016 - Differences in predictions of ODE models of tumor growth</sup>|BIOMD0000000671_url.xml|MODEL1708250001.sedml|True| | | |
|[BIOMD0000000672](https://www.ebi.ac.uk/biomodels/BIOMD0000000672)<br/><sup>Brown1997 - Plasma Melatonin Levels</sup>|BIOMD0000000672_url.xml|MODEL1006230019.sedml|True| | | |
|[BIOMD0000000673](https://www.ebi.ac.uk/biomodels/BIOMD0000000673)<br/><sup>Lockwood2006 - Alzheimer's Disease PBPK model</sup>|BIOMD0000000673_url.xml|MODEL1006230054_edited.sedml|False| | | |
|[BIOMD0000000674](https://www.ebi.ac.uk/biomodels/BIOMD0000000674)<br/><sup>Reyes-Palomares2012 - a combined model hepatic polyamine and sulfur aminoacid metabolism - version1</sup>|BIOMD0000000674_url.xml|MODEL1305060000_edited.sedml|True| | | |
|[BIOMD0000000675](https://www.ebi.ac.uk/biomodels/BIOMD0000000675)<br/><sup>Chen2000_CellCycle</sup>|BIOMD0000000675.xml|MODEL1006230004.sedml|False| | | |
|[BIOMD0000000676](https://www.ebi.ac.uk/biomodels/BIOMD0000000676)<br/><sup>Chen2006 - Nitric Oxide Release from Endothelial Cells</sup>|BIOMD0000000676_url.xml|MODEL1006230005.sedml|True| | | |
|[BIOMD0000000677](https://www.ebi.ac.uk/biomodels/BIOMD0000000677)<br/><sup>Holmes2006 - Hill's model of muscle contraction</sup>|BIOMD0000000677_url.xml|MODEL1006230007.sedml|True| | | |
|[BIOMD0000000678](https://www.ebi.ac.uk/biomodels/BIOMD0000000678)<br/><sup>Tomida2003 - Calcium Oscillatory-induced translocation of nuclear factor of activated T cells</sup>|BIOMD0000000678_url.xml|MODEL0912160005.sedml|False| | | |
|[BIOMD0000000679](https://www.ebi.ac.uk/biomodels/BIOMD0000000679)<br/><sup>Waugh2006 - Diabetic Wound Healing - Macrophage Dynamics</sup>|Waugh2006_1.xml|Waugh2006_1.sedml|True| | | |
|[BIOMD0000000680](https://www.ebi.ac.uk/biomodels/BIOMD0000000680)<br/><sup>Waugh2006 - Diabetic Wound Healing - TGF-B Dynamics</sup>|BIOMD0000000680_url.xml|Waugh2006_2.sedml|True| | | |
|[BIOMD0000000681](https://www.ebi.ac.uk/biomodels/BIOMD0000000681)<br/><sup>Waugh2006 - Diabetic Wound Healing - Treated and Untreated Macrophage Dynamics</sup>|BIOMD0000000681_url.xml|Waugh2006_3.sedml|True| | | |
|[BIOMD0000000682](https://www.ebi.ac.uk/biomodels/BIOMD0000000682)<br/><sup>Wierschem2004 - Electrical bursting activity in Pancreatic Islets</sup>|BIOMD0000000682_url.xml|MODEL1006230006.sedml|True| | | |
|[BIOMD0000000683](https://www.ebi.ac.uk/biomodels/BIOMD0000000683)<br/><sup>Wodarz1999 CTL memory response HIV</sup>|MODEL1006230062.xml|MODEL1006230062.sedml|True| | | |
|[BIOMD0000000684](https://www.ebi.ac.uk/biomodels/BIOMD0000000684)<br/><sup>Wodarz2003 - Immunological Memory</sup>|BIOMD0000000684_url.xml|MODEL1006230061.sedml|True| | | |
|[BIOMD0000000685](https://www.ebi.ac.uk/biomodels/BIOMD0000000685)<br/><sup>Wodarz2003 - Cytotoxic T lymphocyte cross-priming</sup>|BIOMD0000000685_url.xml|MODEL1006230094.sedml|True| | | |
|[BIOMD0000000687](https://www.ebi.ac.uk/biomodels/BIOMD0000000687)<br/><sup>Wodarz2007 - Cytomegalovirus infection model with cytotoxic T lymphocyte response</sup>|BIOMD0000000687_url.xml|MODEL1006230052.sedml|True| | | |
|[BIOMD0000000688](https://www.ebi.ac.uk/biomodels/BIOMD0000000688)<br/><sup>Wodarz2007 - Cytomegalovirus infection model with cytotoxic T lymphocyte and natural killer cell response</sup>|BIOMD0000000688_url.xml|MODEL1006230097.sedml|True| | | |
|[BIOMD0000000689](https://www.ebi.ac.uk/biomodels/BIOMD0000000689)<br/><sup>Thiaville2016 - Folate pathway model (PanB overexpression)</sup>|BIOMD0000000689_url.xml|MODEL1602280002.sedml|True| | | |
|[BIOMD0000000690](https://www.ebi.ac.uk/biomodels/BIOMD0000000690)<br/><sup>Thiaville2016 - Folate pathway model (PanB overexpression and THF regulation)</sup>|BIOMD0000000690_url.xml|MODEL1602280003.sedml|True| | | |
|[BIOMD0000000691](https://www.ebi.ac.uk/biomodels/BIOMD0000000691)<br/><sup>Wolf2000 - Cellular interaction on glycolytic oscillations in yeast</sup>|BIOMD0000000691_url.xml|MODEL1006230022.sedml|True| | | |
|[BIOMD0000000692](https://www.ebi.ac.uk/biomodels/BIOMD0000000692)<br/><sup>Phillips2003 - The Mechanism of Ras GTPase Activation by Neurofibromin</sup>|BIOMD0000000692_url.xml|MODEL4968912141.sedml|True| | | |
|[BIOMD0000000693](https://www.ebi.ac.uk/biomodels/BIOMD0000000693)<br/><sup>Wang2008 - Mimicking the inhibitory effect of riluzole on membrane conductance in skeletal fibres</sup>|BIOMD0000000693_url.xml|MODEL7817907010.sedml|True| | | |
|[BIOMD0000000695](https://www.ebi.ac.uk/biomodels/BIOMD0000000695)<br/><sup>FelixGarza2017 - Blue Light Treatment of Psoriasis (simplified)</sup>|BIOMD0000000695_url.xml|MODEL1701090001.sedml|True| | | |
|[BIOMD0000000696](https://www.ebi.ac.uk/biomodels/BIOMD0000000696)<br/><sup>Boada2016 - Incoherent type 1 feed-forward loop (I1-FFL)</sup>|BIOMD0000000696_url.xml|MODEL1511290000.sedml|True| | | |
|[BIOMD0000000698](https://www.ebi.ac.uk/biomodels/BIOMD0000000698)<br/><sup>Reed2004 - Methionine Cycle</sup>|BIOMD0000000698_url.xml|MODEL1006230091.sedml|True| | | |
|[BIOMD0000000699](https://www.ebi.ac.uk/biomodels/BIOMD0000000699)<br/><sup>Caydasi2012 - Regulation of Tem1 by the GAP complex in spindle position cell cycle checkpoint - Ubiquitous association model</sup>|BIOMD0000000699_url.xml|MODEL1202090002_Fig5 i.sedml|False| | | |
|[BIOMD0000000700](https://www.ebi.ac.uk/biomodels/BIOMD0000000700)<br/><sup>Heldt2018 - Proliferation-quiescence decision in response to DNA damage</sup>|BIOMD0000000700_url.xml|figure1.sedml|True| | | |
|[BIOMD0000000701](https://www.ebi.ac.uk/biomodels/BIOMD0000000701)<br/><sup>Caydasi2012 - Inhibition of Tem1 by the GAP complex in Spindle Position Checkpoint</sup>|MODEL1202090001_FINAL.xml|MODEL1202090001_FINAL.sedml|False| | | |
|[BIOMD0000000702](https://www.ebi.ac.uk/biomodels/BIOMD0000000702)<br/><sup>Caydasi2012 - Regulation of Tem1 by the GAP complex in Spindle Position Checkpoint - Ubiquitous inactive model</sup>|BIOMD0000000702_url.xml|MODEL1202090003_Fig5 iii.sedml|True| | | |
|[BIOMD0000000704](https://www.ebi.ac.uk/biomodels/BIOMD0000000704)<br/><sup>Aguda1999 - G2 DNA damage checkpoint</sup>|BIOMD0000000704_url.xml|figure8.sedml|True| | | |
|[BIOMD0000000719](https://www.ebi.ac.uk/biomodels/BIOMD0000000719)<br/><sup>Tsai2014 - Cell cycle duration control by oscillatory Dynamics  in Early Xenopus laevis Embryos</sup>|Tsai2014.xml|tsai2014.sedml|True| | | |
|[BIOMD0000000724](https://www.ebi.ac.uk/biomodels/BIOMD0000000724)<br/><sup>Theinmozhi2018 - Mechanism of PD1 inhibiting TCR signaling in Tumor immune regulation</sup>|Theinmozhi_2018.xml|Theinmozhi_2018.sedml|False| | | |
|[BIOMD0000000731](https://www.ebi.ac.uk/biomodels/BIOMD0000000731)<br/><sup>Robertson-Tessi M 2012 A model of tumor Immune interaction</sup>|22051568_Tessi.xml|22051568_Tessi.sedml|False| | | |
|[BIOMD0000000732](https://www.ebi.ac.uk/biomodels/BIOMD0000000732)<br/><sup>Kirschner1998_Immunotherapy_Tumour</sup>|Kirschner_1998.xml|Kirschner_1998.sedml|False| | | |
|[BIOMD0000000733](https://www.ebi.ac.uk/biomodels/BIOMD0000000733)<br/><sup>Moore_2004_Mathematical model for CML and T cell interaction</sup>|Moore_2004_fig6.xml|Moore_2004_fig6.sedml|True| | | |
|[BIOMD0000000734](https://www.ebi.ac.uk/biomodels/BIOMD0000000734)<br/><sup>Mouse Iron Distribution - Rich and Deficient iron diets (tracer)</sup>|BIOMD0000000734.xml|Parmar2017_Deficient_Rich_tracer.sedml|True| | | |
|[BIOMD0000000735](https://www.ebi.ac.uk/biomodels/BIOMD0000000735)<br/><sup>Mouse Iron Distribution - Adequate iron diet (tracer)</sup>|Parmar2017_Adequate_tracer.xml|Parmar2017_Adequate_tracer.sedml|True| | | |
|[BIOMD0000000736](https://www.ebi.ac.uk/biomodels/BIOMD0000000736)<br/><sup>Mouse Iron Distribution - Adequate iron diet (No Tracer)</sup>|Parmar2017_Adequate_diet_Anemia_NoTracer.xml|Parmar2017_Adequate_diet_Anemia_NoTracer.sedml|True| | | |
|[BIOMD0000000737](https://www.ebi.ac.uk/biomodels/BIOMD0000000737)<br/><sup>Mouse Iron Distribution - Deficient iron diet (No Tracer)</sup>|Parmar2017_Deficient_NoTracer.xml|Parmar2017_Deficient_NoTracer.sedml|True| | | |
|[BIOMD0000000738](https://www.ebi.ac.uk/biomodels/BIOMD0000000738)<br/><sup>Mouse Iron Distribution - Rich iron diet (No Tracer)</sup>|Parmar2017_Rich_NoTracer.xml|Parmar2017_Rich_NoTracer.sedml|True| | | |
|[BIOMD0000000739](https://www.ebi.ac.uk/biomodels/BIOMD0000000739)<br/><sup>Bravo2012 - Modelling blood coagulation factor Va inactivation by APC</sup>|Bravo2012.xml|Bravo2012.sedml|True| | | |
|[BIOMD0000000740](https://www.ebi.ac.uk/biomodels/BIOMD0000000740)<br/><sup>Panteleev2010 - Blood Coagulation: Full Model</sup>|Panteleev2010_full_model.xml|Panteleev2010_full_model.sedml|True| | | |
|[BIOMD0000000741](https://www.ebi.ac.uk/biomodels/BIOMD0000000741)<br/><sup>Eftimie2018 - Cancer and Immune biomarkers</sup>|Eftimie2018.xml|Eftimie2018.sedml|False| | | |
|[BIOMD0000000742](https://www.ebi.ac.uk/biomodels/BIOMD0000000742)<br/><sup>Garcia2018basic - cancer and immune cell count basic model</sup>|Garcia2018basic.xml|Garcia2018basic.sedml|False| | | |
|[BIOMD0000000743](https://www.ebi.ac.uk/biomodels/BIOMD0000000743)<br/><sup>Gallaher2018 - Tumor–Immune dynamics in multiple myeloma</sup>|Gallaher2018.xml|Gallaher2018.sedml|True| | | |
|[BIOMD0000000744](https://www.ebi.ac.uk/biomodels/BIOMD0000000744)<br/><sup>Hu2019 - Pancreatic cancer dynamics</sup>|Hu2019.xml|Hu2019.sedml|True| | | |
|[BIOMD0000000745](https://www.ebi.ac.uk/biomodels/BIOMD0000000745)<br/><sup>Jarrett2018 - trastuzumab-induced immune response in murine HER2+ breast cancer model</sup>|Jarrett2018.xml|Jarrett2018.sedml|True| | | |
|[BIOMD0000000746](https://www.ebi.ac.uk/biomodels/BIOMD0000000746)<br/><sup>Saad2017 - immune checkpoint and BCG in superficial bladder cancer</sup>|Saad2017.xml|Saad2017.sedml|True| | | |
|[BIOMD0000000747](https://www.ebi.ac.uk/biomodels/BIOMD0000000747)<br/><sup>Nagashima2002 - Simulating blood coagulation inhibitory effects</sup>|Nagashima2002.xml|Nagashima2002.sedml|True| | | |
|[BIOMD0000000748](https://www.ebi.ac.uk/biomodels/BIOMD0000000748)<br/><sup>Phan2017 - innate immune in oncolytic virotherapy</sup>|Phan2017.xml|Phan2017.sedml|True| | | |
|[BIOMD0000000749](https://www.ebi.ac.uk/biomodels/BIOMD0000000749)<br/><sup>Reppas2015 - tumor control via alternating immunostimulating and immunosuppressive phases</sup>|Reppas2015.xml|Reppas2015.sedml|True| | | |
|[BIOMD0000000750](https://www.ebi.ac.uk/biomodels/BIOMD0000000750)<br/><sup>Lolas2016 - tumour-induced neoneurogenesis and perineural tumour growth</sup>|Lolas2016.xml|Lolas2016.sedml|True| | | |
|[BIOMD0000000751](https://www.ebi.ac.uk/biomodels/BIOMD0000000751)<br/><sup>Wilkie2013b - immune-induced cancer dormancy and immune evasion-basic</sup>|Wilkie2013b.xml|Wilkie2013b.sedml|True| | | |
|[BIOMD0000000752](https://www.ebi.ac.uk/biomodels/BIOMD0000000752)<br/><sup>Wilkie2013r - immune-induced cancer dormancy and immune evasion-resistance</sup>|Wilkie2013r.xml|Wilkie2013r.sedml|True| | | |
|[BIOMD0000000753](https://www.ebi.ac.uk/biomodels/BIOMD0000000753)<br/><sup>Figueredo2013/1 - immunointeraction base model</sup>|Figueredo2013:1.xml|Figueredo2013:1.sedml|True| | | |
|[BIOMD0000000754](https://www.ebi.ac.uk/biomodels/BIOMD0000000754)<br/><sup>Figueredo2013/2 - immunointeraction model with IL2</sup>|Figueredo2013:2.xml|Figueredo2013:2.sedml|True| | | |
|[BIOMD0000000755](https://www.ebi.ac.uk/biomodels/BIOMD0000000755)<br/><sup>Hansen2019 - Nine species reduced model of blood coagulation</sup>|Hansen2019.xml|Hansen2019.sedml|False| | | |
|[BIOMD0000000756](https://www.ebi.ac.uk/biomodels/BIOMD0000000756)<br/><sup>Figueredo2013/3 - immunointeraction full model</sup>|Figueredo2013:3.xml|Figueredo2013:3.sedml|True| | | |
|[BIOMD0000000757](https://www.ebi.ac.uk/biomodels/BIOMD0000000757)<br/><sup>Abernathy2016 - glioblastoma treatment</sup>|Abernathy2016.xml|Abernathy2016.sedml|True| | | |
|[BIOMD0000000758](https://www.ebi.ac.uk/biomodels/BIOMD0000000758)<br/><sup>Babbs2012 - immunotherapy</sup>|Babbs2012.xml|Babbs2012.sedml|True| | | |
|[BIOMD0000000759](https://www.ebi.ac.uk/biomodels/BIOMD0000000759)<br/><sup>den Breems2015 - macrophage in cancer</sup>|denBreems2015.xml|denBreems2015.sedml|True| | | |
|[BIOMD0000000760](https://www.ebi.ac.uk/biomodels/BIOMD0000000760)<br/><sup>Feizabadi2011/1 - immunodeficiency in cancer core model</sup>|Feizabadi2011_1.xml|Feizabadi2011_1.sedml|True| | | |
|[BIOMD0000000761](https://www.ebi.ac.uk/biomodels/BIOMD0000000761)<br/><sup>Cappuccio2006 - Cancer immunotherapy by interleukin-21</sup>|Cappuccio2006 v2.0.xml|Cappuccio2006 v9.0.sedml|True| | | |
|[BIOMD0000000762](https://www.ebi.ac.uk/biomodels/BIOMD0000000762)<br/><sup>Kuznetsov1994 - Nonlinear dynamics of immunogenic tumors</sup>|Kuznetsov1994.xml|Kuznetsov1994.sedml|True| | | |
|[BIOMD0000000763](https://www.ebi.ac.uk/biomodels/BIOMD0000000763)<br/><sup>Dritschel2018 - A mathematical model of cytotoxic and helper T cell interactions in a tumour microenvironment</sup>|Dritschel2018.xml|Dritschel2018.sedml|True| | | |
|[BIOMD0000000764](https://www.ebi.ac.uk/biomodels/BIOMD0000000764)<br/><sup>Malinzi2019 - chemovirotherapy</sup>|Malinzi2019.xml|Malinzi2019.sedml|True| | | |
|[BIOMD0000000765](https://www.ebi.ac.uk/biomodels/BIOMD0000000765)<br/><sup>Mager2005 - Quasi-equilibrium pharmacokinetic model for drugs exhibiting target-mediated drug disposition</sup>|Mager2005.xml|Mager2005.sedml|True| | | |
|[BIOMD0000000766](https://www.ebi.ac.uk/biomodels/BIOMD0000000766)<br/><sup>Macnamara2015/1 - virotherapy full model</sup>|Macnamara2015:1.xml|Macnamara2015:1.sedml|True| | | |
|[BIOMD0000000767](https://www.ebi.ac.uk/biomodels/BIOMD0000000767)<br/><sup>Macnamara2015/2 - virotherapy virus-free submodel</sup>|Macnamara2015:2.xml|Macnamara2015:2.sedml|True| | | |
|[BIOMD0000000768](https://www.ebi.ac.uk/biomodels/BIOMD0000000768)<br/><sup>Eftimie2010 - immunity to melanoma</sup>|Eftimie2010.xml|Eftimie2010.sedml|True| | | |
|[BIOMD0000000769](https://www.ebi.ac.uk/biomodels/BIOMD0000000769)<br/><sup>Eftimie2017/2 - interaction of Th and macrophage in melanoma</sup>|Eftimie2017:2.xml|Eftimie2017:2.sedml|True| | | |
|[BIOMD0000000770](https://www.ebi.ac.uk/biomodels/BIOMD0000000770)<br/><sup>Eftimie2017/1 - interaction of Th and macrophage</sup>|Eftimie2017:1.xml|Eftimie2017:1.sedml|True| | | |
|[BIOMD0000000771](https://www.ebi.ac.uk/biomodels/BIOMD0000000771)<br/><sup>Bajzer2008 - Modeling of cancer virotherapy with recombinant measles viruses</sup>|Bazjer2008.xml|Bazjer2008.sedml|True| | | |
|[BIOMD0000000772](https://www.ebi.ac.uk/biomodels/BIOMD0000000772)<br/><sup>Wang2019 - A mathematical model of oncolytic virotherapy with time delay</sup>|Wang2019.xml|Wang2019.sedml|True| | | |
|[BIOMD0000000773](https://www.ebi.ac.uk/biomodels/BIOMD0000000773)<br/><sup>Wodarz2018/2 - model with transit amplifying cells</sup>|Wodarz2018:2.xml|Wodarz2018:2.sedml|True| | | |
|[BIOMD0000000774](https://www.ebi.ac.uk/biomodels/BIOMD0000000774)<br/><sup>Wodarz2018/1 - simple model</sup>|Wodarz2018:1.xml|Wodarz2018:1.sedml|True| | | |
|[BIOMD0000000775](https://www.ebi.ac.uk/biomodels/BIOMD0000000775)<br/><sup>Iarosz2015 - brain tumor</sup>|Iarosz2015.xml|Iarosz2015.sedml|True| | | |
|[BIOMD0000000776](https://www.ebi.ac.uk/biomodels/BIOMD0000000776)<br/><sup>Monro2008 - chemotherapy resistance</sup>|Monro2008.xml|Monro2008.sedml|True| | | |
|[BIOMD0000000777](https://www.ebi.ac.uk/biomodels/BIOMD0000000777)<br/><sup>Chakrabarty2010 - A control theory approach to cancer remission aided by an optimal therapy</sup>|Chakrabarty2010.xml|Chakrabarty2010.sedml|False| | | |
|[BIOMD0000000778](https://www.ebi.ac.uk/biomodels/BIOMD0000000778)<br/><sup>Wei2017 - tumor, T cell and cytokine interaction</sup>|Wei2017.xml|Wei2017.sedml|True| | | |
|[BIOMD0000000779](https://www.ebi.ac.uk/biomodels/BIOMD0000000779)<br/><sup>dePillis2009 - Mathematical model creation for cancer chemo-immunotherapy</sup>|dePillis2009.xml|dePillis2009.sedml|True| | | |
|[BIOMD0000000780](https://www.ebi.ac.uk/biomodels/BIOMD0000000780)<br/><sup>Wang2016/1 - oncolytic efficacy of M1 virus-SNTM model</sup>|Wang2016:1.xml|Wang2016:1.sedml|True| | | |
|[BIOMD0000000781](https://www.ebi.ac.uk/biomodels/BIOMD0000000781)<br/><sup>Wang2016/2 - oncolytic efficacy of M1 virus-SNT model</sup>|Wang2016:2.xml|Wang2016:2.sedml|True| | | |
|[BIOMD0000000782](https://www.ebi.ac.uk/biomodels/BIOMD0000000782)<br/><sup>Wang2016/3 - oncolytic efficacy of M1 virus-SN model</sup>|Wang2016:3.xml|Wang2016:3.sedml|True| | | |
|[BIOMD0000000783](https://www.ebi.ac.uk/biomodels/BIOMD0000000783)<br/><sup>Dong2014 - Mathematical modeling on helper t cells in a tumor immune system</sup>|Dong2014.xml|Dong2014.sedml|True| | | |
|[BIOMD0000000784](https://www.ebi.ac.uk/biomodels/BIOMD0000000784)<br/><sup>Lopez2014 - A Validated Mathematical Model of Tumor Growth Including Tumor-Host Interaction and Cell-Mediated Immune Response</sup>|Lopez2014.xml|Lopez2014.sedml|True| | | |
|[BIOMD0000000785](https://www.ebi.ac.uk/biomodels/BIOMD0000000785)<br/><sup>Sotolongo-Costa2003 - Behavior of tumors under nonstationary therapy</sup>|Sotolongo-Costa2003.xml|Sotolongo-Costa2003.sedml|True| | | |
|[BIOMD0000000786](https://www.ebi.ac.uk/biomodels/BIOMD0000000786)<br/><sup>Lipniacki2004 - Mathematical model of NFKB regulatory module</sup>|Lipniacki2004.xml|Lipniacki2004.sedml|True| | | |
|[BIOMD0000000787](https://www.ebi.ac.uk/biomodels/BIOMD0000000787)<br/><sup>Frascoli2014 - A dynamical model of tumour immunotherapy</sup>|Frascoli2014.xml|Frascoli2014.sedml|True| | | |
|[BIOMD0000000788](https://www.ebi.ac.uk/biomodels/BIOMD0000000788)<br/><sup>Schropp2019 - Target-Mediated Drug Disposition Model for Bispecific Antibodies</sup>|Schropp2019.xml|Schropp2019.sedml|True| | | |
|[BIOMD0000000789](https://www.ebi.ac.uk/biomodels/BIOMD0000000789)<br/><sup>Jenner2018 - treatment of oncolytic virus</sup>|Jenner2018.xml|Jenner2018.sedml|True| | | |
|[BIOMD0000000790](https://www.ebi.ac.uk/biomodels/BIOMD0000000790)<br/><sup>Alvarez2019 - A nonlinear mathematical model of cell-mediated immune response for tumor phenotypic heterogeneity</sup>|Alvarez2019.xml|Alvarez2019.sedml|True| | | |
|[BIOMD0000000791](https://www.ebi.ac.uk/biomodels/BIOMD0000000791)<br/><sup>Wilson2012 - tumor vaccine efficacy</sup>|Wilson2012.xml|Wilson2012.sedml|True| | | |
|[BIOMD0000000792](https://www.ebi.ac.uk/biomodels/BIOMD0000000792)<br/><sup>Hu2019 - Modeling Pancreatic Cancer Dynamics with Immunotherapy</sup>|Hu2019.xml|Hu2019.sedml|True| | | |
|[BIOMD0000000794](https://www.ebi.ac.uk/biomodels/BIOMD0000000794)<br/><sup>Benary2019 - Controlling NFKB dynamics by B-TrCP</sup>|Benary2019.xml|Benary2019.sedml|True| | | |
|[BIOMD0000000795](https://www.ebi.ac.uk/biomodels/BIOMD0000000795)<br/><sup>Chen2011/2 - bone marrow invasion relative model</sup>|Chen2011:2.xml|Chen2011:2.sedml|True| | | |
|[BIOMD0000000796](https://www.ebi.ac.uk/biomodels/BIOMD0000000796)<br/><sup>Yang2012 - cancer growth with angiogenesis</sup>|Yang2012.xml|Yang2012.sedml|True| | | |
|[BIOMD0000000797](https://www.ebi.ac.uk/biomodels/BIOMD0000000797)<br/><sup>Hu2018 - Dynamics of tumor-CD4+-cytokine-host cells interactions with treatments</sup>|Hu2018.xml|Hu2018.sedml|True| | | |
|[BIOMD0000000798](https://www.ebi.ac.uk/biomodels/BIOMD0000000798)<br/><sup>Sharp2019 - AML</sup>|Sharp2019.xml|Sharp2019.sedml|True| | | |
|[BIOMD0000000799](https://www.ebi.ac.uk/biomodels/BIOMD0000000799)<br/><sup>Cucuianu2010 - A hypothetical-mathematical model of acute myeloid leukaemia pathogenesis</sup>|Cucuianu2010.xml|Cucuianu2010.sedml|False| | | |
|[BIOMD0000000800](https://www.ebi.ac.uk/biomodels/BIOMD0000000800)<br/><sup>Precup2012 - Mathematical modeling of cell dynamics after allogeneic bone marrow transplantation</sup>|Precup2012.xml|Precup2012.sedml|True| | | |
|[BIOMD0000000801](https://www.ebi.ac.uk/biomodels/BIOMD0000000801)<br/><sup>Sturrock2015 - glioma growth</sup>|Sturrock2015.xml|Sturrock2015.sedml|True| | | |
|[BIOMD0000000802](https://www.ebi.ac.uk/biomodels/BIOMD0000000802)<br/><sup>Hoffman2018- ADCC against cancer</sup>|Hoffman2017.xml|Hoffman2017.sedml|True| | | |
|[BIOMD0000000803](https://www.ebi.ac.uk/biomodels/BIOMD0000000803)<br/><sup>Park2019 - IL7 receptor signaling in T cells</sup>|Park2019.xml|Park2019.sedml|True| | | |
|[BIOMD0000000804](https://www.ebi.ac.uk/biomodels/BIOMD0000000804)<br/><sup>Koenders2015 - multiple myeloma</sup>|Koenders2015.xml|Koenders2015.sedml|True| | | |
|[BIOMD0000000805](https://www.ebi.ac.uk/biomodels/BIOMD0000000805)<br/><sup>Al-Husari2013 - pH and lactate in tumor</sup>|Al-Husari2013.xml|Al-Husari2013.sedml|True| | | |
|[BIOMD0000000807](https://www.ebi.ac.uk/biomodels/BIOMD0000000807)<br/><sup>Fassoni2019 - Oncogenesis encompassing mutations and genetic instability</sup>|model.xml|Fassoni2019 - 5A.sedml|False| | | |
|[BIOMD0000000808](https://www.ebi.ac.uk/biomodels/BIOMD0000000808)<br/><sup>Kronik2008 - Improving alloreactive CTL immunotherapy for malignant gliomas using a simulation model of their interactive dynamics</sup>|Kronik2008.xml|Kronik2008.sedml|True| | | |
|[BIOMD0000000809](https://www.ebi.ac.uk/biomodels/BIOMD0000000809)<br/><sup>Malinzi2018 - tumour-immune interaction model</sup>|Malinzi2018 - tumour-immune interaction model.xml|Malinzi2018 - tumour-immune interaction model.sedml|False| | | |
|[BIOMD0000000810](https://www.ebi.ac.uk/biomodels/BIOMD0000000810)<br/><sup>Ganguli2018-immuno regulatory mechanisms in tumor microenvironment</sup>|Ganguli2018-immuno regulatory mechanisms in tumor microenvironment.xml|Ganguli2018-immuno regulatory mechanisms in tumor microenvironment.sedml|False| | | |
|[BIOMD0000000811](https://www.ebi.ac.uk/biomodels/BIOMD0000000811)<br/><sup>He2017 - A mathematical model of pancreatic cancer with two kinds of treatments</sup>|He2017.xml|He2017.sedml|True| | | |
|[BIOMD0000000812](https://www.ebi.ac.uk/biomodels/BIOMD0000000812)<br/><sup>Galante2012 - B7-H1 and a Mathematical Model for Cytotoxic T Cell and Tumor Cell Interaction</sup>|Galante2012.xml|Galante2012.sedml|True| | | |
|[BIOMD0000000813](https://www.ebi.ac.uk/biomodels/BIOMD0000000813)<br/><sup>Anderson2015 - Qualitative behavior of systems of tumor-CD4+-cytokine interactions with treatments</sup>|Anderson2015.xml|Anderson2015.sedml|True| | | |
|[BIOMD0000000814](https://www.ebi.ac.uk/biomodels/BIOMD0000000814)<br/><sup>Perez-Garcia19 - Computational design of improved standardized chemotherapy protocols for grade 2 oligodendrogliomas</sup>|Perez-Garcia19 Computational design of improved standardized chemotherapy protocols for grade 2 oligodendrogliomas.xml|Perez-Garcia19 Computational design of improved standardized chemotherapy protocols for grade 2 oligodendrogliomas.sedml|False| | | |
|[BIOMD0000000815](https://www.ebi.ac.uk/biomodels/BIOMD0000000815)<br/><sup>Chrobak2011 - A mathematical model of induced cancer-adaptive immune system competition</sup>|Chrobak2011.xml|Chrobak2011.sedml|True| | | |
|[BIOMD0000000818](https://www.ebi.ac.uk/biomodels/BIOMD0000000818)<br/><sup>Lee2008 - ERK and PI3K signal integration by Myc</sup>|Lee2008.xml|Lee2008.sedml|True| | | |
|[BIOMD0000000823](https://www.ebi.ac.uk/biomodels/BIOMD0000000823)<br/><sup>Varusai2018 - Dynamic modelling of the mTOR signalling network reveals complex emergent behaviours conferred by DEPTOR</sup>|Varusai2018.xml|Varusai2018.sedml|True| | | |
|[BIOMD0000000825](https://www.ebi.ac.uk/biomodels/BIOMD0000000825)<br/><sup>Greene2019 - Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment</sup>|Greene2019 - Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.xml|Greene2019 - Differentiate Spontaneous and Induced Evolution to Drug Resistance During Cancer Treatment.sedml|False| | | |
|[BIOMD0000000826](https://www.ebi.ac.uk/biomodels/BIOMD0000000826)<br/><sup>Shin_2018_EGFR-PYK2-c-Met interaction network_model</sup>|Shin2018.xml|Shin2018.sedml|True| | | |
|[BIOMD0000000828](https://www.ebi.ac.uk/biomodels/BIOMD0000000828)<br/><sup>Jung2019 - Regulating glioblastoma signaling pathways and anti-invasion therapy - core control model</sup>|Jung2019 model.xml|Jung2019 simulation.sedml|False| | | |
|[BIOMD0000000830](https://www.ebi.ac.uk/biomodels/BIOMD0000000830)<br/><sup>GiantsosAdams2013 - Growth of glycocalyx under static conditions</sup>|Giantsos-Adams2013.xml|Giantsos-Adams2013.sedml|True| | | |
|[BIOMD0000000831](https://www.ebi.ac.uk/biomodels/BIOMD0000000831)<br/><sup>Smith1980 - Hypothalamic Regulation</sup>|Smith1980_HypothalamicRegulation.xml|Smith1980_HypothalamicRegulation.sedml|False| | | |
|[BIOMD0000000832](https://www.ebi.ac.uk/biomodels/BIOMD0000000832)<br/><sup>Shin2016 - Unveiling Hidden Dynamics of Hippo Signalling</sup>|Shin2016.xml|Shin2016.sedml|True| | | |
|[BIOMD0000000833](https://www.ebi.ac.uk/biomodels/BIOMD0000000833)<br/><sup>DiCamillo2016 - Insulin signalling pathway - Rule-based model</sup>|DiCamillo2016.xml|DiCamillo2016.sedml|True| | | |
|[BIOMD0000000834](https://www.ebi.ac.uk/biomodels/BIOMD0000000834)<br/><sup>Verma2016 - Ca(2+) Signal Propagation Along Hepatocyte Cords</sup>|Verma2016.xml|Verma2016.sedml|True| | | |
|[BIOMD0000000835](https://www.ebi.ac.uk/biomodels/BIOMD0000000835)<br/><sup>Rao2014 - Fatty acid beta-oxidation (reduced model)</sup>|Rao2014.xml|Rao2014.sedml|True| | | |
|[BIOMD0000000836](https://www.ebi.ac.uk/biomodels/BIOMD0000000836)<br/><sup>Radosavljevic2009_BioterroristAttack_PanicProtection_1</sup>|Radosavljevic2009.xml|Radosavljevic2009.sedml|True| | | |
|[BIOMD0000000837](https://www.ebi.ac.uk/biomodels/BIOMD0000000837)<br/><sup>Hanson2016 - Toxicity Management in CAR T cell therapy for B-ALL</sup>|Hanson2016.xml|Hanson2016.sedml|True| | | |
|[BIOMD0000000838](https://www.ebi.ac.uk/biomodels/BIOMD0000000838)<br/><sup>Tsur2019 - Response of patients with melanoma to immune checkpoint blockade</sup>|Tsur2019.xml|Tsur2019.sedml|True| | | |
|[BIOMD0000000839](https://www.ebi.ac.uk/biomodels/BIOMD0000000839)<br/><sup>Almeida2019 - Transcription-based circadian mechanism controls the duration of molecular clock states in response to signaling inputs</sup>|Almeida2019.xml|Almeida2019.sedml|True| | | |
|[BIOMD0000000840](https://www.ebi.ac.uk/biomodels/BIOMD0000000840)<br/><sup>Caldwell2019 - The Vicodin abuse problem</sup>|Caldwell2019.xml|Caldwell2019.sedml|True| | | |
|[BIOMD0000000842](https://www.ebi.ac.uk/biomodels/BIOMD0000000842)<br/><sup>Heitzler2012 - GPCR signalling</sup>|MODEL1012080000.xml|MODEL1012080000.sedml|True| | | |
|[BIOMD0000000843](https://www.ebi.ac.uk/biomodels/BIOMD0000000843)<br/><sup>Dudziuk2019 - Biologically sound formal model of Hsp70 heat induction</sup>|Dudziuk2019.xml|Dudziuk2019.sedml|True| | | |
|[BIOMD0000000844](https://www.ebi.ac.uk/biomodels/BIOMD0000000844)<br/><sup>Viertel2019 - A Computational model of the mammalian external tufted cell</sup>|Viertel2019.xml|Viertel2019.sedml|True| | | |
|[BIOMD0000000845](https://www.ebi.ac.uk/biomodels/BIOMD0000000845)<br/><sup>Gulbudak2019.1 - Heterogeneous viral strategies promote coexistence in virus-microbe systems (Lytic)</sup>|Gulbudak2019.1.Lytic.xml|Gulbudak2019.1.Lytic.sedml|True| | | |
|[BIOMD0000000846](https://www.ebi.ac.uk/biomodels/BIOMD0000000846)<br/><sup>Gulbudak2019.2 - Heterogeneous viral strategies promote coexistence in virus-microbe systems (Chronic)</sup>|Gulbudak2019.2.Chronic.xml|Gulbudak2019.2.Chronic.sedml|False| | | |
|[BIOMD0000000847](https://www.ebi.ac.uk/biomodels/BIOMD0000000847)<br/><sup>Adams2019 - The regulatory role of shikimate in plant phenylalanine metabolism</sup>|Adams2019.xml|Adams2019.sedml|True| | | |
|[BIOMD0000000848](https://www.ebi.ac.uk/biomodels/BIOMD0000000848)<br/><sup>FatehiChenar2018 - Mathematical model of immune response to hepatitis B</sup>|FatehiChenar2018.xml|FatehiChenar2018.sedml|True| | | |
|[BIOMD0000000849](https://www.ebi.ac.uk/biomodels/BIOMD0000000849)<br/><sup>Potassium balance in lactating and non-lactating dairy cows</sup>|Berg2017.xml|Berg2017.sedml|True| | | |
|[BIOMD0000000850](https://www.ebi.ac.uk/biomodels/BIOMD0000000850)<br/><sup>Jenner2019 - Oncolytic virotherapy for tumours following a Gompertz growth law</sup>|Jenner2019.xml|Jenner2019.sedml|True| | | |
|[BIOMD0000000851](https://www.ebi.ac.uk/biomodels/BIOMD0000000851)<br/><sup>Ho2019 - Mathematical models of transmission dynamics and vaccine strategies in Hong Kong during the 2017-2018 winter influenza season (Simple)</sup>|Ho2019.xml|Ho2019.sedml|True| | | |
|[BIOMD0000000852](https://www.ebi.ac.uk/biomodels/BIOMD0000000852)<br/><sup>Andersen2017 - Mathematical modelling as a proof of concept for MPNs as a human inflammation model for cancer development</sup>|Andersen2017.xml|Andersen2017.sedml|True| | | |
|[BIOMD0000000853](https://www.ebi.ac.uk/biomodels/BIOMD0000000853)<br/><sup>Smolen2018 - Paradoxical LTP maintenance with inhibition of protein synthesis and the proteasome</sup>|Smolen2018.xml|Smolen2018.sedml|True| | | |
|[BIOMD0000000854](https://www.ebi.ac.uk/biomodels/BIOMD0000000854)<br/><sup>Gray2016 - The Akt switch model</sup>|Gray2016.xml|Gray2016.sedml|True| | | |
|[BIOMD0000000855](https://www.ebi.ac.uk/biomodels/BIOMD0000000855)<br/><sup>Cooper2015 - Modeling the effects of systemic mediators on the inflammatory phase of wound healing</sup>|Cooper2015.xml|Cooper2015.sedml|True| | | |
|[BIOMD0000000856](https://www.ebi.ac.uk/biomodels/BIOMD0000000856)<br/><sup>Budding yeast size control by titration of nuclear sites</sup>|Heldt2018.xml|Heldt2018.sedml|True| | | |
|[BIOMD0000000857](https://www.ebi.ac.uk/biomodels/BIOMD0000000857)<br/><sup>Larbat2016.1 - Modeling the diversion of primary carbon flux into secondary metabolism under variable nitrate and light or dark conditions (Base Model)</sup>|Larbat2016.1.xml|Larbat2016.1.sedml|True| | | |
|[BIOMD0000000858](https://www.ebi.ac.uk/biomodels/BIOMD0000000858)<br/><sup>Larbat2016.2 - Modeling the diversion of primary carbon flux into secondary metabolism under variable nitrate and light or dark conditions (Light Dark Cycles)</sup>|Larbat2016.2.xml|Larbat2016.2.sedml|False| | | |
|[BIOMD0000000859](https://www.ebi.ac.uk/biomodels/BIOMD0000000859)<br/><sup>Larbat2016.3 - Modeling the diversion of primary carbon flux into secondary metabolism under variable nitrate and light or dark conditions (Light Dark Cycles with Minimum Starch Adaption)</sup>|Larbat2016.3.xml|Larbat2016.3.sedml|False| | | |
|[BIOMD0000000860](https://www.ebi.ac.uk/biomodels/BIOMD0000000860)<br/><sup>Proctor2017- Role of microRNAs in osteoarthritis (Positive Feedforward Incoherent By MicroRNA)_1</sup>|proctor2017_model4.xml|proctor2017_model4.sedml|True| | | |
|[BIOMD0000000861](https://www.ebi.ac.uk/biomodels/BIOMD0000000861)<br/><sup>Bachmann2011 - Division of labor by dual feedback regulators controls JAK2/STAT5 signaling over broad ligand range</sup>|Bachmann2011.xml|Bachmann2011.sedml|True| | | |
|[BIOMD0000000862](https://www.ebi.ac.uk/biomodels/BIOMD0000000862)<br/><sup>Proctor2017- Role of microRNAs in osteoarthritis (Positive Feedback By Micro RNA)</sup>|Proctor2017_model0.xml|Proctor2017_model0.sedml|True| | | |
|[BIOMD0000000863](https://www.ebi.ac.uk/biomodels/BIOMD0000000863)<br/><sup>Kosinsky2018 - Radiation and PD-(L)1 treatment combinations</sup>|Kosinsky2018.xml|Kosinsky2018.sedml|True| | | |
|[BIOMD0000000864](https://www.ebi.ac.uk/biomodels/BIOMD0000000864)<br/><sup>Proctor2017- Role of microRNAs in osteoarthritis (Negative Feedback By MicroRNA)</sup>|Proctor2017_model1.xml|Proctor2017_model1.sedml|True| | | |
|[BIOMD0000000865](https://www.ebi.ac.uk/biomodels/BIOMD0000000865)<br/><sup>Nikolaev2019 - Immunobiochemical reconstruction of influenza lung infection-melanoma skin cancer interactions</sup>|Nikolaev2019.xml|Nikolaev2019.sedml|True| | | |
|[BIOMD0000000866](https://www.ebi.ac.uk/biomodels/BIOMD0000000866)<br/><sup>Simon2019 - NIK-dependent p100 processing into p52, Michaelis-Menten, SBML 2v4</sup>|Simon2019.xml|Simon2019.sedml|True| | | |
|[BIOMD0000000867](https://www.ebi.ac.uk/biomodels/BIOMD0000000867)<br/><sup>Coulibaly2019 - Interleukin-15 Signaling in HIF-1a Regulation in Natural Killer Cells</sup>|Coulibaly2019.xml|Coulibaly2019.sedml|True| | | |
|[BIOMD0000000868](https://www.ebi.ac.uk/biomodels/BIOMD0000000868)<br/><sup>Simon2019 - NIK-dependent p100 processing into p52, Mass Action, SBML 2v4</sup>|simon2019_model2.xml|simon2019_model2.sedml|True| | | |
|[BIOMD0000000869](https://www.ebi.ac.uk/biomodels/BIOMD0000000869)<br/><sup>Simon2019 - NIK-dependent p100 processing into p52 and IkBd degradation, Michaelis-Menten, SBML 2v4</sup>|Simon2019_model3.xml|Simon2019_model3.sedml|True| | | |
|[BIOMD0000000870](https://www.ebi.ac.uk/biomodels/BIOMD0000000870)<br/><sup>Simon2019 - NIK-dependent p100 processing into p52 and IkBd degradation, mass action, SBML 2v4</sup>|Simon2019_model4.xml|Simon2019_model4.sedml|False| | | |
|[BIOMD0000000871](https://www.ebi.ac.uk/biomodels/BIOMD0000000871)<br/><sup>NIK-dependent p100 processing into p52 with RelB binding and IkBd degradation, mass action, SBML 2v4</sup>|Simon2019_Figure3b.xml|Simon2019_Figure3b.sedml|True| | | |
|[BIOMD0000000872](https://www.ebi.ac.uk/biomodels/BIOMD0000000872)<br/><sup>Verma2016 - HIV and HPV co-infection, T-cell response</sup>|verma2017.xml|verma2017.sedml|True| | | |
|[BIOMD0000000873](https://www.ebi.ac.uk/biomodels/BIOMD0000000873)<br/><sup>Soni2018 - IL6 induced M2 Phenotype in Leishmania major infected macrophage</sup>|Soni2018.xml|Soni2018.sedml|True| | | |
|[BIOMD0000000874](https://www.ebi.ac.uk/biomodels/BIOMD0000000874)<br/><sup>Perelson1993 - HIVinfection_CD4Tcells_ModelA</sup>|Perelson1993.xml|Perelson1993.sedml|True| | | |
|[BIOMD0000000875](https://www.ebi.ac.uk/biomodels/BIOMD0000000875)<br/><sup>Nelson2000- HIV-1 general model 1</sup>|Nelson2000.xml|Nelson2000.sedml|True| | | |
|[BIOMD0000000876](https://www.ebi.ac.uk/biomodels/BIOMD0000000876)<br/><sup>Aavani2019 - The role of CD4 T cells in immune system activation and viral reproduction in a simple model for HIV infection</sup>|Aavani2019.xml|Aavani2019.sedml|True| | | |
|[BIOMD0000000877](https://www.ebi.ac.uk/biomodels/BIOMD0000000877)<br/><sup>Ontah2019 - Dynamic analysis of a tumor treatment model using oncolytic virus and chemotherapy with saturated infection rate</sup>|Ontah2019.xml|Ontah2019.sedml|True| | | |
|[BIOMD0000000878](https://www.ebi.ac.uk/biomodels/BIOMD0000000878)<br/><sup>Lenbury2001_InsulinKineticsModel_A</sup>|Lenbury2001.xml|Lenbury2001.sedml|True| | | |
|[BIOMD0000000879](https://www.ebi.ac.uk/biomodels/BIOMD0000000879)<br/><sup>Rodrigues2019 - A mathematical model for chemoimmunotherapy of chronic lymphocytic leukemia</sup>|Rodrigues2019.xml|Rodrigues2019.sedml|True| | | |
|[BIOMD0000000880](https://www.ebi.ac.uk/biomodels/BIOMD0000000880)<br/><sup>Trisilowati2018 - Optimal control of tumor-immune system interaction with treatment</sup>|Trisilowati2018.xml|Trisilowati2018.sedml|True| | | |
|[BIOMD0000000881](https://www.ebi.ac.uk/biomodels/BIOMD0000000881)<br/><sup>Kogan2013 - A mathematical model for the immunotherapeutic control of the TH1 TH2 imbalance in melanoma</sup>|Kogan2013.xml|Kogan2013.sedml|True| | | |
|[BIOMD0000000882](https://www.ebi.ac.uk/biomodels/BIOMD0000000882)<br/><sup>Munz2009 - Zombie SIZRC</sup>|munz2000.xml|munz2000.sedml|True| | | |
|[BIOMD0000000883](https://www.ebi.ac.uk/biomodels/BIOMD0000000883)<br/><sup>Giani2019 - Computational modeling to predict MAP3K8 effects as mediator of resistance to vemurafenib in thyroid cancer stem cells</sup>|Giani2019.xml|Giani2019.sedml|True| | | |
|[BIOMD0000000884](https://www.ebi.ac.uk/biomodels/BIOMD0000000884)<br/><sup>Cortes2019 - Optimality of the spontaneous prophage induction rate.</sup>|Cortes2019.xml|Cortes2019.sedml|False| | | |
|[BIOMD0000000885](https://www.ebi.ac.uk/biomodels/BIOMD0000000885)<br/><sup>Sumana2018 - Mathematical modeling of cancer-immune system, considering the role of antibodies.</sup>|Sumana2018.xml|Sumana2018.sedml|True| | | |
|[BIOMD0000000886](https://www.ebi.ac.uk/biomodels/BIOMD0000000886)<br/><sup>Dubey2008 - Modeling the interaction between avascular cancerous cells and acquired immune response</sup>|Dubey2008.xml|Dubey2008.sedml|True| | | |
|[BIOMD0000000887](https://www.ebi.ac.uk/biomodels/BIOMD0000000887)<br/><sup>Lim2014 - HTLV-I infection A dynamic struggle between viral persistence and host immunity</sup>|Lim2014.xml|Lim2014.sedml|True| | | |
|[BIOMD0000000888](https://www.ebi.ac.uk/biomodels/BIOMD0000000888)<br/><sup>Unni2019 - Mathematical Modeling, Analysis, and Simulation of Tumor Dynamics with Drug Interventions</sup>|unni2019.xml|unni2019.sedml|True| | | |
|[BIOMD0000000889](https://www.ebi.ac.uk/biomodels/BIOMD0000000889)<br/><sup>Fribourg2014 - Model of influenza A virus infection dynamics of viral antagonism and innate immune response.</sup>|Fribourg2014.xml|Fribourg2014.sedml|True| | | |
|[BIOMD0000000890](https://www.ebi.ac.uk/biomodels/BIOMD0000000890)<br/><sup>Bhattacharya2014 - A mathematical model of the sterol regulatory element binding protein 2 cholesterol biosynthesis pathway</sup>|Bhattacharya2014.xml|Bhattacharya2014.sedml|True| | | |
|[BIOMD0000000891](https://www.ebi.ac.uk/biomodels/BIOMD0000000891)<br/><sup>Khajanchi2019 - Stability Analysis of a Mathematical Model forGlioma-Immune Interaction under OptimalTherapy</sup>|Khajanchi2019.xml|Khajanchi2019.sedml|True| | | |
|[BIOMD0000000892](https://www.ebi.ac.uk/biomodels/BIOMD0000000892)<br/><sup>Sandip2013 - Modeling the dynamics of hepatitis C virus with combined antiviral drug therapy: interferon and ribavirin.</sup>|Sandip2013.xml|Sandip2013.sedml|True| | | |
|[BIOMD0000000893](https://www.ebi.ac.uk/biomodels/BIOMD0000000893)<br/><sup>GonzalezMiranda2013 - The effect of circadian oscillations on biochemical cell signaling by NF-κB</sup>|GonzalezMiranda2013.xml|GonzalezMiranda2013.sedml|True| | | |
|[BIOMD0000000894](https://www.ebi.ac.uk/biomodels/BIOMD0000000894)<br/><sup>Bose2011 - Noise-assisted interactions of tumor and immune cells</sup>|Bose2011.xml|Bose2011.sedml|True| | | |
|[BIOMD0000000895](https://www.ebi.ac.uk/biomodels/BIOMD0000000895)<br/><sup>Schokker2013 - A mathematical model representing cellular immune development and response to Salmonella of chicken intestinal tissue</sup>|Schokker2013.xml|Schokker2013.sedml|True| | | |
|[BIOMD0000000896](https://www.ebi.ac.uk/biomodels/BIOMD0000000896)<br/><sup>Szymanska2009 - Mathematical modeling of heat shock protein synthesis in response to temperature change</sup>|Szymanska2009.xml|Szymanska2009.sedml|True| | | |
|[BIOMD0000000897](https://www.ebi.ac.uk/biomodels/BIOMD0000000897)<br/><sup>Khajanchi2015 - The combined effects of optimal control in cancer remission</sup>|Khajanchi2015.xml|Khajanchi2015.sedml|False| | | |
|[BIOMD0000000898](https://www.ebi.ac.uk/biomodels/BIOMD0000000898)<br/><sup>Jiao2018 - Feedback regulation in a stem cell model with acute myeloid leukaemia</sup>|Jiao2018.xml|Jiao2018.sedml|True| | | |
|[BIOMD0000000899](https://www.ebi.ac.uk/biomodels/BIOMD0000000899)<br/><sup>Ota2015 - Positive regulation of Rho GTPase activity by RhoGDIs as a result of their direct interaction with GAPs (GDI integrated)</sup>|Ota2015_GDI-integrated.xml|Ota2015_GDI-integrated.sedml|True| | | |
|[BIOMD0000000900](https://www.ebi.ac.uk/biomodels/BIOMD0000000900)<br/><sup>Bianca2013 - Persistence analysis in a Kolmogorov-type model for cancer-immune system competition</sup>|Bianca2013.xml|Bianca2013.sedml|True| | | |
|[BIOMD0000000902](https://www.ebi.ac.uk/biomodels/BIOMD0000000902)<br/><sup>Wang2019 - A mathematical model of oncolytic virotherapy with time delay</sup>|Wang2019.xml|Wang2019.sedml|True| | | |
|[BIOMD0000000903](https://www.ebi.ac.uk/biomodels/BIOMD0000000903)<br/><sup>Solis-perez2019 - A fractional mathematical model of breast cancer competition model</sup>|Solis-perez2019.xml|Solis-perez2019.sedml|True| | | |
|[BIOMD0000000904](https://www.ebi.ac.uk/biomodels/BIOMD0000000904)<br/><sup>Admon2017 - Modelling tumor growth with immune response and drug using ordinary differential equations</sup>|Admon2017.xml|Admon2017.sedml|True| | | |
|[BIOMD0000000905](https://www.ebi.ac.uk/biomodels/BIOMD0000000905)<br/><sup>Dubey2007 - A mathematical model for the effect of toxicant on the immune system (with toxicant effect) Model2</sup>|Dubey2007_model2.xml|Dubey2007_model2.sedml|True| | | |
|[BIOMD0000000906](https://www.ebi.ac.uk/biomodels/BIOMD0000000906)<br/><sup>Dubey2007 - A mathematical model for the effect of toxicant on the immune system (without toxicant effect) Model1</sup>|Dubey2007_model1.xml|Dubey2007_model1.sedml|True| | | |
|[BIOMD0000000907](https://www.ebi.ac.uk/biomodels/BIOMD0000000907)<br/><sup>HeberleRazquinNavas2019 - The PI3K and MAPK/p38 pathways control stress granuleassembly in a hierarchical manner model 3</sup>|Navas2019_model3.xml|Navas2019_model3.sedml|True| | | |
|[BIOMD0000000908](https://www.ebi.ac.uk/biomodels/BIOMD0000000908)<br/><sup>dePillis2013 - Mathematical modeling of regulatory T cell effects on renal cell carcinoma treatment</sup>|dePillis2013.xml|dePillis2013.sedml|True| | | |
|[BIOMD0000000909](https://www.ebi.ac.uk/biomodels/BIOMD0000000909)<br/><sup>dePillis2003 - The dynamics of an optimally controlled tumor model: A case study</sup>|dePillis2003.xml|dePillis2003.sedml|True| | | |
|[BIOMD0000000910](https://www.ebi.ac.uk/biomodels/BIOMD0000000910)<br/><sup>Isaeva2008 - Modelling of Anti-Tumour Immune Response Immunocorrective Effect of Weak Centimetre Electromagnetic Waves</sup>|Isaeva2008.xml|Isaeva2008.sedml|True| | | |
|[BIOMD0000000911](https://www.ebi.ac.uk/biomodels/BIOMD0000000911)<br/><sup>Merola2008 - An insight into tumor dormancy equilibrium via the analysis of its domain of attraction</sup>|Merola2008.xml|Merola2008.sedml|True| | | |
|[BIOMD0000000912](https://www.ebi.ac.uk/biomodels/BIOMD0000000912)<br/><sup>Caravagna2010 - Tumour suppression by immune system</sup>|Caravagna2010.xml|Caravagna2010.sedml|False| | | |
|[BIOMD0000000913](https://www.ebi.ac.uk/biomodels/BIOMD0000000913)<br/><sup>dePillis2008 - Optimal control of mixed immunotherapy and chemotherapy of tumors</sup>|dePillis2008.xml|dePillis2008.sedml|True| | | |
|[BIOMD0000000914](https://www.ebi.ac.uk/biomodels/BIOMD0000000914)<br/><sup>Parra_Guillen2013 -  Mathematical model approach to describe tumour response in mice after vaccine administration_model1</sup>|Parra_Guillen2013.xml|Parra_Guillen2013.sedml|True| | | |
|[BIOMD0000000915](https://www.ebi.ac.uk/biomodels/BIOMD0000000915)<br/><sup>Sun2018 - Instantaneous mutation rate in cancer initiation and progression</sup>|Sun2018.xml|Sun2018.sedml|True| | | |
|[BIOMD0000000916](https://www.ebi.ac.uk/biomodels/BIOMD0000000916)<br/><sup>Kraan199_Kinetics of Cortisol Metabolism and Excretion.</sup>|Kraan1992.xml|Kraan1992.sedml|True| | | |
|[BIOMD0000000917](https://www.ebi.ac.uk/biomodels/BIOMD0000000917)<br/><sup>Phillips2007_AscendingArousalSystem_SleepWakeDynamics</sup>|Phillips2007_Curated.xml|Phillips2007.sedml|False| | | |
|[BIOMD0000000918](https://www.ebi.ac.uk/biomodels/BIOMD0000000918)<br/><sup>Schwarz2018-Cdk Activity Threshold Determines Passage through the Restriction Point</sup>|Schwarz2018.xml|Schwarz2018.sedml|False| | | |
|[BIOMD0000000919](https://www.ebi.ac.uk/biomodels/BIOMD0000000919)<br/><sup>Ledzewicz2013 - On optimal chemotherapy with a strongly targeted agent for a model of tumor immune system interactions with generalized logistic growth</sup>|Ledzewicz2013.xml|Ledzewicz2013.sedml|False| | | |
|[BIOMD0000000920](https://www.ebi.ac.uk/biomodels/BIOMD0000000920)<br/><sup>Jarrett2015 - Modelling the interaction between immune response, bacterial dynamics and inflammatory damage</sup>|Jarrett2015.xml|Jarrett2015.sedml|True| | | |
|[BIOMD0000000921](https://www.ebi.ac.uk/biomodels/BIOMD0000000921)<br/><sup>Khajanchi2017 - Uniform Persistence and Global Stability for a Brain Tumor and Immune System Interaction</sup>|khajanchi2017.xml|khajanchi2017.sedml|True| | | |
|[BIOMD0000000922](https://www.ebi.ac.uk/biomodels/BIOMD0000000922)<br/><sup>Turner2015-Human/Mosquito ELP Model</sup>|Turner2015_ELP.xml|Turner2015_ELP.sedml|False| | | |
|[BIOMD0000000923](https://www.ebi.ac.uk/biomodels/BIOMD0000000923)<br/><sup>Liò2012_Modelling osteomyelitis_Control Model</sup>|Liò2012_Modelling osteomyelitis_Control Model.xml|Liò2012_Modelling osteomyelitis_Control Model.sedml|True| | | |
|[BIOMD0000000925](https://www.ebi.ac.uk/biomodels/BIOMD0000000925)<br/><sup>Dunster2016 - Nondimensional Coagulation Model</sup>|Dunster2016_Nondimensional_Model_Curated.xml|Dunster2016_Nondimensional_Model1.sedml|True| | | |
|[BIOMD0000000926](https://www.ebi.ac.uk/biomodels/BIOMD0000000926)<br/><sup>Rhodes2019 - Immune-Mediated theory of Metastasis</sup>|Rhodes2019-Immune-Mediated theory of Metastasis_V1.xml|Rhodes2019-Immune-Mediated theory of Metastasis_V1.sedml|True| | | |
|[BIOMD0000000927](https://www.ebi.ac.uk/biomodels/BIOMD0000000927)<br/><sup>Grigolon2018-Responses to auxin signals</sup>|Grigolon2018_fig1b.xml|Grigolon2018_fig1b.sedml|True| | | |
|[BIOMD0000000929](https://www.ebi.ac.uk/biomodels/BIOMD0000000929)<br/><sup>Li2016 - Model for pancreatic cancer patients receiving immunotherapy</sup>|Li2016.xml|Li2016.sedml|False| | | |
|[BIOMD0000000930](https://www.ebi.ac.uk/biomodels/BIOMD0000000930)<br/><sup>Liu2017 - chemotherapy targeted model of tumor immune system</sup>|Liu2017.xml|Liu2017.sedml|True| | | |
|[BIOMD0000000931](https://www.ebi.ac.uk/biomodels/BIOMD0000000931)<br/><sup>Voliotis2019-GnRH Pulse Generation</sup>|Voliotis2019.xml|Voliotis2019.sedml|True| | | |
|[BIOMD0000000933](https://www.ebi.ac.uk/biomodels/BIOMD0000000933)<br/><sup>Kosiuk2015-Geometric analysis of the Goldbeter minimal model for the embryonic cell cycle</sup>|Kosiuk2015.xml|Kosiuk2015.sedml|True| | | |
|[BIOMD0000000935](https://www.ebi.ac.uk/biomodels/BIOMD0000000935)<br/><sup>Ferrel2011 - Cdk1 and APC regulation in cell cycle in Xenopus laevis</sup>|Ferrel2011.xml|Ferrel2011.sedml|True| | | |
|[BIOMD0000000936](https://www.ebi.ac.uk/biomodels/BIOMD0000000936)<br/><sup>ferrel2011 - autonomous biochemical oscillator in cell cycle in Xenopus laevis v2</sup>|Ferrel2011_V2.xml|Ferrel2011_V2.sedml|True| | | |
|[BIOMD0000000937](https://www.ebi.ac.uk/biomodels/BIOMD0000000937)<br/><sup>Ferrel2011 - Autonomous biochemical oscillator in regulation of CDK1, Plk1, and APC in Xenopus Laevis cell cycle</sup>|Ferrel2011_V3.xml|Ferrel2011_V3.sedml|True| | | |
|[BIOMD0000000938](https://www.ebi.ac.uk/biomodels/BIOMD0000000938)<br/><sup>Gerard2013 - Model 3 - Embryonic-type eukaryotic Cell Cycle regulation based on negative feedback between Cdk/cyclin and APC and competitive inhibition between Cdk/cyclin and securin for polyubiquitylation_1</sup>|Gerard2013.xml|Gerard2013.sedml|True| | | |
|[BIOMD0000000940](https://www.ebi.ac.uk/biomodels/BIOMD0000000940)<br/><sup>Tang2019 - Pharmacology modelling of AURKB and ZAK interaction in TNBC</sup>|Tang2019.xml|Tang2019.sedml|False| | | |
|[BIOMD0000000941](https://www.ebi.ac.uk/biomodels/BIOMD0000000941)<br/><sup>Gerard2010 - Progression of mammalian cell cycle by successive activation of various cyclin cdk complexes</sup>|gerard2010.xml|gerard2010.sedml|True| | | |
|[BIOMD0000000942](https://www.ebi.ac.uk/biomodels/BIOMD0000000942)<br/><sup>Sible2007 - Mitotic cell cycle mecanism in Xenopus Laevis</sup>|Sible2007.xml|Sible2007.sedml|True| | | |
|[BIOMD0000000943](https://www.ebi.ac.uk/biomodels/BIOMD0000000943)<br/><sup>Hat2016 - Reponse of p53 System to irradiation in cell fate decision making</sup>|Hat2016.xml|Hat2016.sedml|True| | | |
|[BIOMD0000000944](https://www.ebi.ac.uk/biomodels/BIOMD0000000944)<br/><sup>Goldbeter2013-Oscillatory activity of cyclin-dependent kinases in the cell cycle</sup>|Goldbeter2013.xml|Goldbeter2013.sedml|True| | | |
|[BIOMD0000000945](https://www.ebi.ac.uk/biomodels/BIOMD0000000945)<br/><sup>Evans2004 - Cell based mathematical model of topotecan</sup>|Evans2004.xml|Evans2004.sedml|True| | | |
|[BIOMD0000000946](https://www.ebi.ac.uk/biomodels/BIOMD0000000946)<br/><sup>Evans2005 - Compartmental model for antineoplastic drug topotecan in breast cancer cells</sup>|Evans2005.xml|Evans2005.sedml|True| | | |
|[BIOMD0000000947](https://www.ebi.ac.uk/biomodels/BIOMD0000000947)<br/><sup>Lee2017 - Paracetamol first-pass metabolism PK model</sup>|Lee2017_Paracetamol_Metabolism.xml|Evans2005.sedml|True| | | |
|[BIOMD0000000948](https://www.ebi.ac.uk/biomodels/BIOMD0000000948)<br/><sup>Landberg2009 - Alkylresorcinol Dose Response</sup>|Landberg2009.xml|Landberg2009.sedml|True| | | |
|[BIOMD0000000949](https://www.ebi.ac.uk/biomodels/BIOMD0000000949)<br/><sup>Chitnis2008 - Mathematical model of malaria transmission</sup>|Chitnis2008.xml|Chitnis2008.sedml|True| | | |
|[BIOMD0000000950](https://www.ebi.ac.uk/biomodels/BIOMD0000000950)<br/><sup>Chitnis2012 - Model Rift Valley Fever transmission between cattle and mosquitoes (Model 1)</sup>|Chitnis2012_model_1.xml|Chitnis2012_model_1.sedml|True| | | |
|[BIOMD0000000952](https://www.ebi.ac.uk/biomodels/BIOMD0000000952)<br/><sup>Rodenfels2019 - Heat Oscillations Driven by the Embryonic Cell Cycle Reveal the Energetic Costs of Signaling</sup>|Rodenfels2019_V1.xml|Rodenfels2019_V1.sedml|False| | | |
|[BIOMD0000000953](https://www.ebi.ac.uk/biomodels/BIOMD0000000953)<br/><sup>Queralt2006 - Initiation of mitotic exit by downregulation of PP2A in budding yeast</sup>|queralt2006_final.xml|queralt2006_final.sedml|True| | | |
|[BIOMD0000000955](https://www.ebi.ac.uk/biomodels/BIOMD0000000955)<br/><sup>Giordano2020 - SIDARTHE model of COVID-19 spread in Italy</sup>|Giordano2020.xml|Giordano2020.sedml|True| | | |
|[BIOMD0000000956](https://www.ebi.ac.uk/biomodels/BIOMD0000000956)<br/><sup>Bertozzi2020 - SIR model of scenarios of COVID-19 spread in CA and NY</sup>|Bertozzi2020.xml|Bertozzi2020.sedml|True| | | |
|[BIOMD0000000957](https://www.ebi.ac.uk/biomodels/BIOMD0000000957)<br/><sup>Roda2020 - SIR model of COVID-19 spread in Wuhan</sup>|Roda2020.xml|Roda2020.sedml|True| | | |
|[BIOMD0000000958](https://www.ebi.ac.uk/biomodels/BIOMD0000000958)<br/><sup>Ndairou2020 - early-stage transmission dynamics of COVID-19 in Wuhan</sup>|Ndairou2020.xml|Ndairou2020.sedml|False| | | |
|[BIOMD0000000959](https://www.ebi.ac.uk/biomodels/BIOMD0000000959)<br/><sup>Kok2020 - IFNalpha-induced signaling in Huh7.5 cells</sup>|Kok2020.xml|Kok2020.sedml|True| | | |
|[BIOMD0000000960](https://www.ebi.ac.uk/biomodels/BIOMD0000000960)<br/><sup>Paiva2020 - SEIAHRD model of transmission dynamics of COVID-19</sup>|Paiva2020.xml|Paiva2020.sedml|True| | | |
|[BIOMD0000000961](https://www.ebi.ac.uk/biomodels/BIOMD0000000961)<br/><sup>McDougal2017 - Metabolism in ischemic cardiomyocytes</sup>|McDougal2017.xml|McDougal2017.sedml|True| | | |
|[BIOMD0000000962](https://www.ebi.ac.uk/biomodels/BIOMD0000000962)<br/><sup>Zhao2020 - SUQC model of COVID-19 transmission dynamics in Wuhan, Hubei, and China</sup>|Zhao2020.xml|Zhao2020.sedml|False| | | |
|[BIOMD0000000963](https://www.ebi.ac.uk/biomodels/BIOMD0000000963)<br/><sup>Weitz2020 - SIR model of COVID-19 transmission with shielding</sup>|Weitz2020.xml|Weitz2020.sedml|True| | | |
|[BIOMD0000000964](https://www.ebi.ac.uk/biomodels/BIOMD0000000964)<br/><sup>Mwalili2020 - SEIR model of COVID-19 transmission and environmental pathogen prevalence</sup>|Mwalili2020.xml|Mwalili2020.sedml|True| | | |
|[BIOMD0000000965](https://www.ebi.ac.uk/biomodels/BIOMD0000000965)<br/><sup>LeBeau1999 - IP3-dependent intracellular calcium oscillations due to agonist stimulation from Cholecytokinin</sup>|LeBeau1999_Phosphorylation_CCK.xml|LeBeau1999_Phosphorylation_CCK.sedml|True| | | |
|[BIOMD0000000966](https://www.ebi.ac.uk/biomodels/BIOMD0000000966)<br/><sup>Cui2008 - in vitro transcriptional response of zinc homeostasis system in Escherichia coli</sup>|Cui2008.xml|Cui2008.sedml|True| | | |
|[BIOMD0000000967](https://www.ebi.ac.uk/biomodels/BIOMD0000000967)<br/><sup>McLean1991 - Behaviour of HIV in the presence of zidovudine</sup>|McLean1991.xml|McLean1991.sedml|True| | | |
|[BIOMD0000000968](https://www.ebi.ac.uk/biomodels/BIOMD0000000968)<br/><sup>Palmer2008 - Negative Feedback in IL-7 mediated Jak-Stat signaling</sup>|Palmer2008.xml|Palmer2008.sedml|True| | | |
|[BIOMD0000000969](https://www.ebi.ac.uk/biomodels/BIOMD0000000969)<br/><sup>Cuadros2020 - SIHRD spatiotemporal model of COVID-19 transmission in Ohio</sup>|Cuadros2020.xml|Cuadros2020.sedml|True| | | |
|[BIOMD0000000970](https://www.ebi.ac.uk/biomodels/BIOMD0000000970)<br/><sup>Hou2020 - SEIR model of COVID-19 transmission in Wuhan</sup>|Hou2020.xml|Hou2020.sedml|True| | | |
|[BIOMD0000000971](https://www.ebi.ac.uk/biomodels/BIOMD0000000971)<br/><sup>Tang2020 - Estimation of transmission risk of COVID-19 and impact of public health interventions</sup>|Tang2020.xml|Tang2020.sedml|True| | | |
|[BIOMD0000000972](https://www.ebi.ac.uk/biomodels/BIOMD0000000972)<br/><sup>Tang2020 - Estimation of transmission risk of COVID-19 and impact of public health interventions - update</sup>|Tang2020.xml|Tang2020.sedml|True| | | |
|[BIOMD0000000973](https://www.ebi.ac.uk/biomodels/BIOMD0000000973)<br/><sup>Dasgupta2020 - Reduced model of receptor clusturing and aggregation</sup>|Dasgupta2020.xml|Dasgupta2020.sedml|True| | | |
|[BIOMD0000000974](https://www.ebi.ac.uk/biomodels/BIOMD0000000974)<br/><sup>Carcione2020 - Deterministic SEIR simulation of a COVID-19 outbreak</sup>|Carcione2020.xml|Carcione2020.sedml|True| | | |
|[BIOMD0000000975](https://www.ebi.ac.uk/biomodels/BIOMD0000000975)<br/><sup>Leloup2004 - Mammalian Circadian Rhythm models for 23.8 and 24.2 hours timeperiod</sup>|Leloup2004_Set1.xml|Leloup2004_Set1.sedml|True| | | |
|[BIOMD0000000976](https://www.ebi.ac.uk/biomodels/BIOMD0000000976)<br/><sup>Ghanbari2020 - forecasting the second wave of COVID-19 in Iran</sup>|Ghanbari2020.xml|Ghanbari2020.sedml|True| | | |
|[BIOMD0000000977](https://www.ebi.ac.uk/biomodels/BIOMD0000000977)<br/><sup>Sarkar2020 - SAIR model of COVID-19 transmission with quarantine measures in India</sup>|Sarkar2020.xml|Sarkar2020.sedml|True| | | |
|[BIOMD0000000978](https://www.ebi.ac.uk/biomodels/BIOMD0000000978)<br/><sup>Mukandavire2020 - SEIR model of early COVID-19 transmission in South Africa</sup>|Mukandavire2020.xml|Mukandavire2020.sedml|True| | | |
|[BIOMD0000000979](https://www.ebi.ac.uk/biomodels/BIOMD0000000979)<br/><sup>Malkov2020 - SEIRS model of COVID-19 transmission with reinfection</sup>|Malkov2020.xml|Malkov2020.sedml|True| | | |
|[BIOMD0000000980](https://www.ebi.ac.uk/biomodels/BIOMD0000000980)<br/><sup>Malkov2020 - SEIRS model of COVID-19 transmission with time-varying R values and reinfection</sup>|Malkov2020.xml|Malkov2020.sedml|True| | | |
|[BIOMD0000000981](https://www.ebi.ac.uk/biomodels/BIOMD0000000981)<br/><sup>Wan2020 - risk estimation and prediction of the transmission of COVID-19 in maninland China excluding Hubei province</sup>|Wan2020.xml|Wan2020.sedml|True| | | |
|[BIOMD0000000982](https://www.ebi.ac.uk/biomodels/BIOMD0000000982)<br/><sup>Law2020 - SIR model of COVID-19 transmission in Malyasia with time-varying parameters</sup>|Law2020.xml|Law2020.sedml|True| | | |
|[BIOMD0000000983](https://www.ebi.ac.uk/biomodels/BIOMD0000000983)<br/><sup>Zongo2020 - model of COVID-19 transmission dynamics under containment measures in France</sup>|Zongo2020.xml|Zongo2020.sedml|True| | | |
|[BIOMD0000000984](https://www.ebi.ac.uk/biomodels/BIOMD0000000984)<br/><sup>Fang2020 - SEIR model of COVID-19 transmission considering government interventions in Wuhan</sup>|Fang2020.xml|Fang2020.sedml|True| | | |
|[BIOMD0000000985](https://www.ebi.ac.uk/biomodels/BIOMD0000000985)<br/><sup>Gex-Fabry1984 - model of receptor-mediated endocytosis of EGF in BALB/c 3T3 cells</sup>|Gex-Fabry1984.xml|Gex-Fabry1984.sedml|True| | | |
|[BIOMD0000000986](https://www.ebi.ac.uk/biomodels/BIOMD0000000986)<br/><sup>Aubry1995 - Multi-compartment model of fluid-phase endocytosis kinetics in Dictyostelium discoideum</sup>|Aubry1995.xml|Aubry1995.sedml|True| | | |
|[BIOMD0000000987](https://www.ebi.ac.uk/biomodels/BIOMD0000000987)<br/><sup>Aubry1995 - Nine-compartment model of fluid-phase endocytosis kinetics in Dictyostelium discoideum</sup>|Aubry1995.xml|Aubry1995.sedml|True| | | |
|[BIOMD0000000988](https://www.ebi.ac.uk/biomodels/BIOMD0000000988)<br/><sup>Westerhoff2020 - systems biology model of the coronavirus pandemic 2020</sup>|Westerhoff2020.xml|Westerhoff2020.sedml|True| | | |
|[BIOMD0000000989](https://www.ebi.ac.uk/biomodels/BIOMD0000000989)<br/><sup>Strasen2018 - TGFb SMAD Signalling - Dose dependent dynamics upon TGFb stimulation</sup>|MODEL1712050001.xml|MODEL1712050001.sedml|False| | | |
|[BIOMD0000000990](https://www.ebi.ac.uk/biomodels/BIOMD0000000990)<br/><sup>Strasen2018 - TGFb SMAD Signalling - Degradation of 25pM ligand (TGFb)</sup>|MODEL1712050002.xml|MODEL1712050002.sedml|False| | | |
|[BIOMD0000000991](https://www.ebi.ac.uk/biomodels/BIOMD0000000991)<br/><sup>Okuonghae2020 - SEAIR model of COVID-19 transmission in Lagos, Nigeria</sup>|Okuonghae2020.xml|Okuonghae2020.sedml|True| | | |
|[BIOMD0000000994](https://www.ebi.ac.uk/biomodels/BIOMD0000000994)<br/><sup>Strasen2018 - TGFb SMAD Signalling - Restimulation with 5pM TGFb at 3hr</sup>|MODEL1712050003.xml|MODEL1712050003.sedml|True| | | |
|[BIOMD0000000995](https://www.ebi.ac.uk/biomodels/BIOMD0000000995)<br/><sup>Strasen2018 - TGFb SMAD Signalling - Restimulation with 5pM TGFb at 8hr</sup>|MODEL1712050004.xml|MODEL1712050004.sedml|True| | | |
|[BIOMD0000000996](https://www.ebi.ac.uk/biomodels/BIOMD0000000996)<br/><sup>Strasen2018 - TGFb SMAD Signalling - Restimulation with 100pM TGFb at 6hr</sup>|MODEL1712050005.xml|MODEL1712050005.sedml|True| | | |
|[BIOMD0000000997](https://www.ebi.ac.uk/biomodels/BIOMD0000000997)<br/><sup>Strasen2018 - TGFb SMAD Signalling - DRB treatment</sup>|MODEL1712050006.xml|MODEL1712050006.sedml|True| | | |
|[BIOMD0000000998](https://www.ebi.ac.uk/biomodels/BIOMD0000000998)<br/><sup>Strasen2018 - TGFb SMAD Signalling Class 1</sup>|MODEL1712050007.xml|MODEL1712050007.sedml|True| | | |
|[BIOMD0000000999](https://www.ebi.ac.uk/biomodels/BIOMD0000000999)<br/><sup>Strasen2018 - TGFb SMAD Signalling Class 2</sup>|MODEL1712050008.xml|MODEL1712050008.sedml|True| | | |
|[BIOMD0000001000](https://www.ebi.ac.uk/biomodels/BIOMD0000001000)<br/><sup>Strasen2018 - TGFb SMAD Signalling Class 3</sup>|MODEL1712050009.xml|MODEL1712050009.sedml|True| | | |
|[BIOMD0000001001](https://www.ebi.ac.uk/biomodels/BIOMD0000001001)<br/><sup>Strasen2018 - TGFb SMAD Signalling Class 4</sup>|MODEL1712050010.xml|MODEL1712050010.sedml|True| | | |
|[BIOMD0000001002](https://www.ebi.ac.uk/biomodels/BIOMD0000001002)<br/><sup>Strasen2018 - TGFb SMAD Signalling Class 5</sup>|MODEL1712050011.xml|MODEL1712050011.sedml|True| | | |
|[BIOMD0000001003](https://www.ebi.ac.uk/biomodels/BIOMD0000001003)<br/><sup>Strasen2018 - TGFb SMAD Signalling Class 6</sup>|MODEL17120500012.xml|MODEL17120500012.sedml|True| | | |
|[BIOMD0000001004](https://www.ebi.ac.uk/biomodels/BIOMD0000001004)<br/><sup>Intosalmi2015 - Th17 core network model</sup>|Intosalmi2015.xml|Intosalmi2015.sedml|False| | | |
|[BIOMD0000001005](https://www.ebi.ac.uk/biomodels/BIOMD0000001005)<br/><sup>Bae2017 - Mathematical analysis of circadian disruption and metabolic re-entrainment of hepatic gluconeogenesis</sup>|Bae2018.xml|Bae2018.sedml|True| | | |
|[BIOMD0000001006](https://www.ebi.ac.uk/biomodels/BIOMD0000001006)<br/><sup>Ciliberto2005 - Steady states and oscillations in the p53/Mdm2 network</sup>|Ciliberto2005.xml|Ciliberto2005.sedml|True| | | |
|[BIOMD0000001008](https://www.ebi.ac.uk/biomodels/BIOMD0000001008)<br/><sup>Scaramellini1997 - Two-receptor:One-transducer (2R1T) model for analysis of interactions between agonists</sup>|Scaramellini1997.xml|Scaramellini1997.sedml|True| | | |
|[BIOMD0000001009](https://www.ebi.ac.uk/biomodels/BIOMD0000001009)<br/><sup>Zhang2007 - Mechanism of DNA damage response (Model2)</sup>|Zhang2007_M2_low_dose.xml|Zhang2007_M2_high_dose.sedml|False| | | |
|[BIOMD0000001011](https://www.ebi.ac.uk/biomodels/BIOMD0000001011)<br/><sup>Leon-Triana2020 - CAR T-cell therapy in B-cell acute lymphoblastic leukaemia</sup>|Leon-Triana2020 (eqs 4).xml|Leon-Triana2020 (eqs 4).sedml|True| | | |
|[BIOMD0000001012](https://www.ebi.ac.uk/biomodels/BIOMD0000001012)<br/><sup>Leon-Triana2020 - CAR T-cell therapy in B-cell acute lymphoblastic leukaemia with contribution from immature B cells</sup>|Leon-Triana2020 (eqs 3).xml|Leon-Triana2020 (eqs 3).sedml|True| | | |
|[BIOMD0000001014](https://www.ebi.ac.uk/biomodels/BIOMD0000001014)<br/><sup>Leon-Triana2021 - Competition between tumour cells and dual-target CAR T-cells</sup>|Leon-Triana2021 (eqs 3-6).xml|Leon-Triana2021 (eqs 3-6).sedml|True| | | |
|[BIOMD0000001015](https://www.ebi.ac.uk/biomodels/BIOMD0000001015)<br/><sup>Jarrah2014 - mathematical model of the immune response in muscle degeneration and subsequent regeneration in Duchenne muscular dystrophy in mdx mice</sup>|Jarrah2014.xml|Jarrah2014.sedml|True| | | |
|[BIOMD0000001016](https://www.ebi.ac.uk/biomodels/BIOMD0000001016)<br/><sup>Bakshi2020 - Truncated minimal model of alternative pathway of complement system</sup>|Bakshi2020 truncated minimal model.xml|Bakshi2020 truncated minimal model.sedml|False| | | |
|[BIOMD0000001017](https://www.ebi.ac.uk/biomodels/BIOMD0000001017)<br/><sup>Bakshi2020 - Minimal model of alternative pathway of complement system</sup>|Bakshi2020 minimal model.xml|Bakshi2020 minimal model.sedml|True| | | |
|[BIOMD0000001018](https://www.ebi.ac.uk/biomodels/BIOMD0000001018)<br/><sup>Bakshi2020 - Properdin model of alternative pathway of complement system</sup>|Bakshi2020 properdin model.xml|Bakshi2020 properdin model.sedml|False| | | |
|[BIOMD0000001019](https://www.ebi.ac.uk/biomodels/BIOMD0000001019)<br/><sup>Barros2021 - CARTmath, Mathematical Model of CAR-T Immunotherapy in HDLM-2 cell line</sup>|Barros2021_HDLM2.xml|Barros2021_HDLM2.sedml|False| | | |
|[BIOMD0000001020](https://www.ebi.ac.uk/biomodels/BIOMD0000001020)<br/><sup>Barros2021 - CARTmath, Mathematical Model of CAR-T Immunotherapy in Raji Cell Line</sup>|Barros2021_RAJI.xml|Barros2021_RAJI.sedml|False| | | |
|[BIOMD0000001023](https://www.ebi.ac.uk/biomodels/BIOMD0000001023)<br/><sup>Alharbi2020 - An ODE-based model of the dynamics of tumor cell progression and its effects on normal cell growth and immune system functionality</sup>|Alharbi2020.xml|Alharbi2020 - Fig 5.sedml|True| | | |
|[BIOMD0000001024](https://www.ebi.ac.uk/biomodels/BIOMD0000001024)<br/><sup>Chaudhury2020 - Lotka-Volterra mathematical model of CAR-T cell and tumour kinetics</sup>|Chaudhury2020 Eq 4-5.xml|Chaudhury2020 Eq 4-5 - Fig 3(C) simulation.sedml|True| | | |
|[BIOMD0000001026](https://www.ebi.ac.uk/biomodels/BIOMD0000001026)<br/><sup>Kurlovics2021 - Metformin partitioning between plasma and RBC with independent Kin and Kout coefficients</sup>|Kurlovics2021.xml|Kurlovics2021.sedml|False| | | |
|[BIOMD0000001027](https://www.ebi.ac.uk/biomodels/BIOMD0000001027)<br/><sup>Zake2021 - PBPK model of metformin in mice: single dose peroral</sup>|Zake2021_Metformin+Mice+PO.xml|Zake2021_Metformin+Mice+PO.sedml|True| | | |
|[BIOMD0000001028](https://www.ebi.ac.uk/biomodels/BIOMD0000001028)<br/><sup>Zake2021 - PBPK model of metformin in humans, single PO dose</sup>|Zake2021_Metformin+Human+single+PO+dose.xml|Zake2021_Metformin+Human+single+PO+dose.sedml|True| | | |
|[BIOMD0000001029](https://www.ebi.ac.uk/biomodels/BIOMD0000001029)<br/><sup>Zake2021 - PBPK model of metformin in humans, eight PO administrations with 12h interval</sup>|Zake2021_Metformin+Human+multiple+PO+dose.xml|Zake2021_Metformin+Human+multiple+PO+dose.sedml|True| | | |
|[BIOMD0000001032](https://www.ebi.ac.uk/biomodels/BIOMD0000001032)<br/><sup>Al-Tuwairqi2020 - Dynamics of cancer radiovirotherapy - Phase II treatment</sup>|Al-Tuwairqi2020 - Phase II radiovirotherapy treatment.xml|Al-Tuwairqi2020 - Fig8 simulation.sedml|False| | | |
|[BIOMD0000001033](https://www.ebi.ac.uk/biomodels/BIOMD0000001033)<br/><sup>Almuallem2020 - Virus-macrophage-tumour interactions in oncolytic viral therapies</sup>|Almuallem2020.xml|Almuallem2020 - Fig6.sedml|True| | | |
|[BIOMD0000001034](https://www.ebi.ac.uk/biomodels/BIOMD0000001034)<br/><sup>Bunimovich-Mendrazitsky2007 - Mathematical model of BCG immunotherapy</sup>|Bunimovich-Mendrazitsky2007.xml|Bunimovich-Mendrazitsky2007 - Fig4.sedml|True| | | |
|[BIOMD0000001036](https://www.ebi.ac.uk/biomodels/BIOMD0000001036)<br/><sup>Cappuccio2007 - Tumor-immune system interactions and determination of the optimal therapeutic protocol in immunotherapy</sup>|Cappuccio2007.xml|Cappuccio2007 - Fig1.sedml|False| | | |
|[BIOMD0000001037](https://www.ebi.ac.uk/biomodels/BIOMD0000001037)<br/><sup>Alharbi2019 - Tumor-normal model (TNM) of the development of tumor cells and their impact on normal cell dynamics</sup>|Alharbi2019 TNM.xml|Alharbi2019 TNM - Fig10.sedml|False| | | |
|[BIOMD0000001038](https://www.ebi.ac.uk/biomodels/BIOMD0000001038)<br/><sup>Alharbi2019 - Tumor-normal-vitamins model (TNVM) of the effects of vitamins on delaying the growth of tumor cells</sup>|Alharbi2019 TNVM.xml|Alharbi2019 TNVM - Fig11.sedml|False| | | |
|[BIOMD0000001039](https://www.ebi.ac.uk/biomodels/BIOMD0000001039)<br/><sup>Zake2021 - PBPK model of metformin in mice: single dose intavenous</sup>|Zake2021_Metformin+Mice+IV.xml|Zake2021_Metformin+Mice+IV.sedml|False| | | |
|[BIOMD0000001040](https://www.ebi.ac.uk/biomodels/BIOMD0000001040)<br/><sup>Kurlovics2021 - Metformin partitioning from plasma to RBC,  single coefficient</sup>|Kurlovics2021_single.xml|Kurlovics2021_single.sedml|False| | | |
|[BIOMD0000001041](https://www.ebi.ac.uk/biomodels/BIOMD0000001041)<br/><sup>Kimmel2021 - T cell competition and stochastic extinction events in CAR T cell therapy</sup>|Kimmel2021.xml|Kimmel2021 - Fig2(a) and (b).sedml|True| | | |
|[BIOMD0000001044](https://www.ebi.ac.uk/biomodels/BIOMD0000001044)<br/><sup>Csikasz-Nagy2006 - Mammalian Cell Cycle model</sup>|Csikasz-Nagy2006.xml|Csikasz-Nagy2006.sedml|True| | | |
|[BIOMD0000001045](https://www.ebi.ac.uk/biomodels/BIOMD0000001045)<br/><sup>Smith&Moore2004 - The SIR model for the spread of HongKong Flu</sup>|Smith and moore2004-the SIR Model for Spread of Disease.xml|Smith and moore2004-the SIR Model for Spread of Disease.sedml|True| | | |
|[BIOMD0000001047](https://www.ebi.ac.uk/biomodels/BIOMD0000001047)<br/><sup>Collier1996 - Delta Notch intercellular signalling and lateral inhibition</sup>|delta_notch.xml|delta_notch.sedml|False| | | |
|[BIOMD0000001048](https://www.ebi.ac.uk/biomodels/BIOMD0000001048)<br/><sup>Siddhartha2002 - Kinetic modelling of cancer therapies</sup>|cancer_therapy.xml|cancer_therapy.sedml|True| | | |
|[BIOMD0000001052](https://www.ebi.ac.uk/biomodels/BIOMD0000001052)<br/><sup>Alharbi2020 - Tumor and immune system competition</sup>|Tumor_cells_immune_system_competition.xml|Tumor_cells_immune_system_competition.sedml|True| | | |
|[BIOMD0000001053](https://www.ebi.ac.uk/biomodels/BIOMD0000001053)<br/><sup>Garde2020 - metabolic oscillations in Bacillus subtilis biofilms</sup>|Garde2020.xml|Garde2020.sedml|True| | | |
|[BIOMD0000001054](https://www.ebi.ac.uk/biomodels/BIOMD0000001054)<br/><sup>Pearce2021 - Fibrin Polymerization</sup>|fibrin_polymerization.xml|fibrin_polymerization.sedml|True| | | |
|[BIOMD0000001055](https://www.ebi.ac.uk/biomodels/BIOMD0000001055)<br/><sup>Jeon2018 - Enzyme clustering in Glucose metabolism</sup>|Enzyme_clustering_in glucose_metabolism.xml|Enzyme_clustering_in glucose_metabolism.sedml|True| | | |
|[BIOMD0000001056](https://www.ebi.ac.uk/biomodels/BIOMD0000001056)<br/><sup>Chulian2021 - feedback signalling in B lymphopoeisis</sup>|chulian2021.xml|chulian2021.sedml|True| | | |
|[BIOMD0000001057](https://www.ebi.ac.uk/biomodels/BIOMD0000001057)<br/><sup>Nikolov2020 - p53-miR34 model</sup>|Nikolov2020.xml|Nikolov2020.sedml|True| | | |
|[BIOMD0000001058](https://www.ebi.ac.uk/biomodels/BIOMD0000001058)<br/><sup>Novak2022 - Mitotic kinase oscillation</sup>|Novak2022.xml|Novak2022.sedml|True| | | |
|[BIOMD0000001059](https://www.ebi.ac.uk/biomodels/BIOMD0000001059)<br/><sup>Stucki2005 - caspase-3 metabolism</sup>|Stucki2005.xml|Stucki2005.sedml|True| | | |
|[BIOMD0000001060](https://www.ebi.ac.uk/biomodels/BIOMD0000001060)<br/><sup>Frank2021 - Macrophage polarization</sup>|Frank2021.xml|Frank2021.sedml|True| | | |
|[BIOMD0000001072](https://www.ebi.ac.uk/biomodels/BIOMD0000001072)<br/><sup>Phillips2013 - physiologically based modeling explaining Mammalian rest/activity patterns</sup>|Phillips2013.xml|Phillips2013.sedml|True| | | |
|[BIOMD0000001077](https://www.ebi.ac.uk/biomodels/BIOMD0000001077)<br/><sup>Adlung2021 - Cell-to-cell variability in JAK2/STAT5 pathway</sup>|Adlung2021 _model_jakstat_pa.xml|Adlung2021 _model_jakstat_pa.sedml|True| | | |
|[BIOMD0000001078](https://www.ebi.ac.uk/biomodels/BIOMD0000001078)<br/><sup>Hammaren-Geissen2022_PPToP_Model12</sup>|Hammaren-Geissen2022_PPToP_Model12_withParameterSets.xml|Hammaren-Geissen2022_PPToP_Model12_withParameterSets.sedml|True| | | |
|[BIOMD0000001079](https://www.ebi.ac.uk/biomodels/BIOMD0000001079)<br/><sup>DeBoeck2021 - Modular approach to modeling the cell cycle, simple cell cycle model</sup>|DeBoeck2021_cellcycle_bistableapc.xml|DeBoeck2021_cellcycle_bistableapc.sedml|True| | | |
|[BIOMD0000001080](https://www.ebi.ac.uk/biomodels/BIOMD0000001080)<br/><sup>DeBoeck2021 - Modular approach to modeling the cell cycle, 5 ODE model with 3 bistable switches</sup>|DeBoeck2021_cellcycle_threeswitches.xml|DeBoeck2021_cellcycle_threeswitches.sedml|True| | | |
